Berry Street and Healthify Merge, Betting on the GLP-1 Health Wave
U.S. nutrition startup Berry Street has merged with Khosla Ventures-backed Indian health and fitness startup Healthify, the companies announced on August 24, 2026. Financial terms were not disclosed. The merged entity will operate under the Berry Street brand in the United States and under the Healthify name in other markets, including India. Berry Street founder Noah Kotlove and Healthify founder Tushar Vashisht will serve as co-CEOs. TechCrunch
The merger brings together two companies with complementary, though overlapping, product lines. Berry Street provides AI-powered nutrition coaching and meal tracking through a network of over 2,000 clinics, and offers insurance-covered GLP-1 care to patients taking medications such as Ozempic, Wegovy, and Mounjaro. GLP-1s are a class of drugs originally developed for diabetes that have become widely used for weight loss. The company claims to have served more than 200,000 people in collaboration with Amazon, Walmart, and other platforms. Berry Street raised $50 million last year in a round led by Northzone, Sofina, and FJ Labs. TechCrunch
Healthify, which has raised over $150 million in total funding per Crunchbase, offers both AI-powered and human fitness and nutritional coaching via its app. The company claims it has served more than 45 million customers to date. Its app includes an AI health coach named Ria that provides meal tracking, personalized diet and workout suggestions, and health insights based on user data. It also offers HealthifySnap, a feature that identifies foods in a photo and tracks them instantly. TechCrunch Last year, Healthify expanded its U.S. operations and began offering GLP-1-aided programs in India. TechCrunch
Healthify has also been building pharmaceutical industry partnerships. Following its existing partnership with Novo Nordisk, the company was in talks to partner with additional weight-loss drugmakers as of December 2025. Reuters At that time, Reuters reported Healthify's cumulative funding at $122 million; the figure now stands at over $150 million per Crunchbase, as cited by TechCrunch. Reuters
Berry Street, for its part, launched a structured GLP-1 Nutrition Pathway Program in September 2025. The program consists of three distinct phases designed to support patients who are starting GLP-1s, currently taking them, or transitioning off them. MedCity News The program adds a clinical-care dimension to the coaching and tracking capabilities that both companies already offer through their apps.
The merger is positioned explicitly around the GLP-1 wave. Vashisht said in a press release that Berry Street gives Healthify "the clinical backbone and coverage infrastructure to deliver its mission to the U.S. market." TechCrunch Khosla Ventures founder Vinod Khosla said the two companies "are building the platform that will redefine metabolic care." TechCrunch Healthify's official website describes the combined entity as "the most advanced insurance-covered AI metabolic health platform." Healthify
The market backdrop is substantial. A JP Morgan report published this year projects that over 30 million people in the U.S. will be on GLP-1 drugs by 2030. TechCrunch The pharma and food industries are both repositioning around that trajectory. Nestle, for instance, is developing new products specifically for GLP-1 users, using AI to identify formulations that serve the dietary needs of people on weight-loss medications. Reuters
The strategic logic of the merger is fairly clear from what each side brings to the table. Berry Street contributes U.S. clinical infrastructure, insurance coverage relationships, and a multi-phase GLP-1 care program. Healthify brings an AI coaching stack already refined at significant consumer scale, an existing Novo Nordisk partnership with more pharma tie-ups in discussion, and deep market penetration in India. The co-CEO structure suggests neither side is folding into the other; the dual-brand strategy preserves existing market recognition in each geography.
What bears watching is whether the combined company can actually execute across two regulatory environments, two payment infrastructures, and two consumer markets with very different GLP-1 adoption curves. India's GLP-1 access and insurance landscape differs sharply from the U.S. system where Berry Street's clinic network and insurance-covered care model operate. The merged entity's ability to productize its AI coaching across both contexts, rather than running parallel stacks, will likely determine whether this is a genuine platform play or a portfolio of adjacent businesses sharing a cap table.
The broader signal here is that the GLP-1 moment is moving past the pharma-only frame. Startups, food conglomerates, and insurance-covered clinical networks are all building infrastructure around what is shaping up to be a durable category of chronic care. Whether 30 million U.S. users materialize by 2030 or not, the capital and partnership activity is already treating that projection as a planning assumption.
